Business Description
InnoCare Pharma Ltd
ISIN : KYG4783B1032
Total Employee Number:
1,259Compare
Compare
Traded in other countries / regions
09969.Hong Kong688428.China33C.GermanyINCPF.USA Index Membership
Hong Kong Stock Connect IPO Date
2020-03-23Description
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.39 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.25 | |||||
Debt-to-EBITDA | 1.86 | |||||
Interest Coverage | 13.53 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 5.91 | |||||
Beneish M-Score | -0.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 48.1 | |||||
3-Year Book Growth Rate | 0.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 19.02 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.14 | |||||
9-Day RSI | 58.42 | |||||
14-Day RSI | 57.96 | |||||
3-1 Month Momentum % | 14.9 | |||||
6-1 Month Momentum % | 12.93 | |||||
12-1 Month Momentum % | -23.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.19 | |||||
Quick Ratio | 4.1 | |||||
Cash Ratio | 3.8 | |||||
Days Inventory | 248.1 | |||||
Days Sales Outstanding | 63.28 | |||||
Days Payable | 279.95 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 91.57 | |||||
Operating Margin % | 27.61 | |||||
Net Margin % | 32.83 | |||||
EBITDA Margin % | 37.77 | |||||
FCF Margin % | 0.52 | |||||
OCF Margin % | 2.98 | |||||
ROE % | 12.47 | |||||
ROA % | 8.77 | |||||
ROIC % | 24.22 | |||||
3-Year ROIIC % | 137.4 | |||||
ROC (Joel Greenblatt) % | 98.34 | |||||
ROCE % | 11.1 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 23.84 | |||||
Forward PE Ratio | 114.28 | |||||
PE Ratio without NRI | 24.2 | |||||
Price-to-Owner-Earnings | 33.72 | |||||
PS Ratio | 7.93 | |||||
PB Ratio | 2.86 | |||||
Price-to-Tangible-Book | 2.87 | |||||
Price-to-Free-Cash-Flow | 1800 | |||||
Price-to-Operating-Cash-Flow | 271.7 | |||||
EV-to-EBIT | 21.57 | |||||
EV-to-Forward-EBIT | 100.53 | |||||
EV-to-EBITDA | 20.21 | |||||
EV-to-Revenue | 7.63 | |||||
EV-to-Forward-Revenue | 7.25 | |||||
EV-to-FCF | 1473.61 | |||||
Price-to-GF-Value | 0.67 | |||||
Price-to-Projected-FCF | 720 | |||||
Price-to-Graham-Number | 1.76 | |||||
| Price-to-Net-Current-Asset-Value | 3.88 | |||||
| Price-to-Net-Cash | 4.57 | |||||
Earnings Yield (Greenblatt) % | 4.64 | |||||
FCF Yield % | 0.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
InnoCare Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 3,130.841 | ||
| EPS (TTM) (HK$) | 0.604 | ||
| Beta | 1.6667 | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 0.97 | ||
| Volatility % | 42.71 | ||
| 14-Day RSI | 57.96 | ||
| 14-Day ATR (HK$) | 0.716917 | ||
| 20-Day SMA (HK$) | 14.281 | ||
| 12-1 Month Momentum % | -23.42 | ||
| 52-Week Range (HK$) | 9.65 - 20.18 | ||
| Shares Outstanding (Mil) | 1,766.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
InnoCare Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
InnoCare Pharma Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 11:00 | In 80 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 10:00 | In 80 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-23 20:30 | 14.27 (-1.59%) | ||
| Second quarter earnings results for 2026 | 2026-08-23 | 14.27 (-1.59%) | ||
| General meeting for 2026 | 2026-06-16 10:00 | 10.96 (-1.26%) | ||
| First quarter earnings results for 2026 | 2026-04-23 | 14.87 (-0.73%) | ||
| Annual report for 2025 | 2026-03-26 | 12.35 (+0.90%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-25 18:00 | 12.04 (+2.03%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-25 | 12.04 (+2.03%) | ||
| Third quarter earnings conference call for 2025 | 2025-11-14 11:00 | 15.10 (+2.72%) |
Show
Entries
InnoCare Pharma Ltd Frequently Asked Questions
What is InnoCare Pharma Ltd(HKSE:09969)'s stock price today?
The current price of HKSE:09969 is HK$14.40. The 52 week high of HKSE:09969 is HK$20.18 and 52 week low is HK$9.65.
When is next earnings date of InnoCare Pharma Ltd(HKSE:09969)?
The next earnings date of InnoCare Pharma Ltd(HKSE:09969) is 2026-11-13 Est..
Does InnoCare Pharma Ltd(HKSE:09969) pay dividends? If so, how much?
InnoCare Pharma Ltd(HKSE:09969) does not pay dividend.
Press Release
Articles on InnoCare Pharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers